Best Vitamin K2 Supplements for Bone Health in 2026

Vitamin K is a cofactor for the enzyme gamma-glutamyl carboxylase, which adds carboxyl groups to specific glutamate residues in vitamin K-dependent proteins — a process called carboxylation. Carboxylation is required for these proteins to bind calcium and become biologically active. **Osteocalcin and bone mineralization.** Osteocalcin is a protein synthesized by osteoblasts (bone-building cells) that becomes activated when carboxylated by K2. Activated (carboxylated) osteocalcin has three calcium-binding domains that bind calcium ions and incorporate them into the hydroxyapatite mineral structure of bone matrix — essentially anchoring calcium in bone. When K2 is insufficient, osteocalcin remains undercarboxylated (ucOC), cannot effectively bind calcium, and bone mineral incorporation is impaired. Blood levels of ucOC are a validated biomarker of K2 status; higher ucOC indicates more severe K2 deficiency. **Matrix GLA protein (MGP) and arterial calcification.** MGP is expressed in vascular smooth muscle cells, chondrocytes, and other soft tissues. Like osteocalcin, it requires carboxylation by K2 to become active. Activated MGP is the primary inhibitor of vascular calcification — it prevents calcium phosphate crystals from forming in arterial walls. Without sufficient K2, MGP remains inactive and cannot suppress arterial calcium deposition. This is the mechanistic basis for the 'calcium paradox': taking calcium without K2 may increase circulating calcium availability, but without activated MGP, that calcium is more vulnerable to depositing in arteries rather than being directed exclusively to bone. **Why MK-7 and not K1 or MK-4?** The three forms differ in their tissue distribution, half-life, and biological activity: - **Vitamin K1 (phylloquinone)**: Found in green vegetables; primarily taken up by the liver for coagulation factor synthesis; relatively poor uptake in bone and vascular tissue. Does not effectively activate osteocalcin or MGP in peripheral tissues. - **MK-4 (menaquinone-4)**: Shorter-chain form; half-life ~6 hours; present in some animal foods. Active in bone and brain tissue. At pharmacological doses (45mg/day, used in Japanese pharmaceutical protocols), MK-4 has strong RCT evidence for bone density. At typical supplement doses (1mg), the 6-hour half-life creates significant gaps in K2 availability unless taken multiple times daily. - **MK-7 (menaquinone-7)**: Long-chain form produced by Bacillus subtilis fermentation (natto); half-life ~3 days; excellent peripheral tissue distribution including bone and vascular tissue. At 100-200mcg/day, MK-7 produces sustained elevated K2 levels that activate osteocalcin and MGP throughout the day. The Rotterdam Study's cardiovascular benefit was specifically associated with MK-7 dietary intake. **The D3 + K2 + calcium stack.** Vitamin D3 increases intestinal calcium absorption — which is beneficial for bone health but also increases circulating calcium. K2 ensures that elevated circulating calcium is directed to bone (via activated osteocalcin) and prevented from depositing in arteries (via activated MGP). The combination of D3 + K2 + calcium is mechanistically coherent: D3 increases calcium availability, K2 directs it appropriately, calcium provides the substrate. Taking high-dose D3 without K2 may increase the theoretical risk of soft tissue calcium deposition.

**MK-7 vs MK-4: which should I choose?** For most users, MK-7 at 100-200mcg/day is the better practical choice. The 3-day half-life means a single daily dose maintains consistently elevated K2 plasma levels. The Rotterdam Study's cardiovascular associations were specifically tied to MK-7 dietary intake. RCTs like Knapen 2013 use MK-7 at 180mcg/day. MK-4 has its own RCT evidence base — particularly at very high doses (45mg/day) used in Japanese clinical trials for osteoporosis. But at typical supplement doses (1mg or less), MK-4's 6-hour half-life means plasma K2 levels from a once-daily supplement will be low for most of the day. If you want MK-4, consider taking it 2-3 times daily, or choose a multi-form product that includes MK-7 for the sustained baseline. **Does K2 MK-7 come from soy?** Most MK-7 is produced by Bacillus subtilis fermentation of soy natto. The fermentation process typically reduces soy protein content significantly, but some products may retain detectable soy allergens. If you have soy sensitivity or allergy, look explicitly for soy-free labeled products (NOW Foods MK-7 on this list is explicitly soy-free). Some premium MK-7 forms (such as MenaQ7 brand) are tested to confirm minimal soy residue. **How much K2 do I need?** The evidence-based range for MK-7 supplementation is 100-200mcg/day. The Knapen 2013 RCT used 180mcg/day for 3 years with significant bone and osteocalcin outcomes. The Rotterdam Study's dietary benefit was associated with menaquinone intakes of approximately 32mcg/day from food — suggesting that even moderate dietary amounts are meaningful. Supplemental 100-200mcg/day is substantially above typical dietary intake and is the range most likely to produce measurable changes in undercarboxylated osteocalcin. **Do I need to take K2 with vitamin D3?** Not required, but increasingly recommended. The rationale: vitamin D3 increases intestinal calcium absorption; K2 directs that calcium appropriately via osteocalcin and MGP activation. Taking high-dose D3 (>2,000 IU/day) without K2 may increase circulating calcium in a context of suboptimal MGP activation. Many integrative medicine practitioners recommend D3 + K2 + calcium as a stack rather than any of the three individually.